title: Free fatty acid binding protein-4 and retinol binding protein-4 in polycystic ovary syndrome: response to simvastatin and metformin therapies.
abstract: Free fatty acid binding protein-4 (FABP4) and retinol binding protein-4 (RBP4) contribute to metabolic syndrome. We investigated serum FABP4 and RBP4 responses to insulin sensitizing and lipid lowering therapies in polycystic ovary syndrome (PCOS). Sixty-two healthy, untreated women with PCOS (age 25.1 ± 3.6 years, BMI: 24.0 ± 4.7 kg/m(2)) were randomized to metformin (n = 24), simvastatin (n = 20) or metformin plus simvastatin (n = 18) for 3 months. Anthropometric measures, fasting blood tests and oral glucose tolerance tests (OGTT) were obtained at the baseline and the end. At the baseline serum FABP4 correlated with obesity (BMI: r = 0.63, p < 0.001), insulin resistance (fasting insulin: r = 0.44, p = 0.0002; QUICKI: r = -0.30, p = 0.02; OGTT-insulin sensitivity index: r = -0.27, p = 0.04), dyslipidemia (HDL: r = -0.26, p = 0.03) and hyperandrogenemia (free-testosterone: r = 0.23, p = 0.03; SHBG: r = -0.28, p = 0.03); while RBP4 correlated with total-cholesterol (r = 0.33, p = 0.009). Multiple regression analysis indicated that t best predictors of serum FABP4 and RBP4 were BMI (β = 1.02, p = 0.0003) and total cholesterol (β = 2326, p = 0.01), respectively. Simvastatin, alone or with metformin did not affect serum FABP4 or RBP4. Serum FABP4 related to the obesity, insulin resistance and inflammation while RBP4 related to lipids. Insulin sensitizing and lipid lowering therapies did not affect FABP4 or RBP4 levels in PCOS.
authors.affiliation: Department of Internal Medicine, Division of Endocrinology, Diabetes and Metabolism, University of California Davis, Davis, CA 95817, USA. sekarakas@ucdavis.edu
authors.forename: Sidika E
authors.initials: SE
authors.lastname: Karakas
authors.forename: Beata
authors.initials: B
authors.lastname: Banaszewska
authors.forename: Robert Z
authors.initials: RZ
authors.lastname: Spaczynski
authors.forename: Leszek
authors.initials: L
authors.lastname: Pawelczyk
authors.forename: Antoni
authors.initials: A
authors.lastname: Duleba
mesh_terms: D000328:Adult; D004359:Drug Therapy, Combination; D050556:Fatty Acid-Binding Proteins / Q000097:blood*; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D008297:Male; D008687:Metformin / Q000627:therapeutic use; D011085:Polycystic Ovary Syndrome / Q000097:blood* / Q000188:drug therapy; D054839:Retinol-Binding Proteins, Plasma / Q000378:metabolism*; D019821:Simvastatin / Q000627:therapeutic use; D055815:Young Adult
chemical_list: C493410:FABP4 protein, human; D050556:Fatty Acid-Binding Proteins; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007004:Hypoglycemic Agents; C101326:RBP4 protein, human; D054839:Retinol-Binding Proteins, Plasma; D008687:Metformin; D019821:Simvastatin